WHO Guidelines For Development of Pediatric Medicines: points to consider in formulation
Annex 5
General Note:
The “points to consider” document should not contain detailed instructions for development but rather it should make reference to relevant literature. Some matters dealt with in the draft on development of multi source products have, therefore, been omitted in this proposal.
Click on the titles below for complete guidelines
TABLE CONTENTS
Development of Pediatric Medicines: points to consider in formulation,
(WHO Technical Report Series 970, 2012 Annex 5,)